Creative Bioarray specializes in identifying potential drug toxicity to different tissues and organs using a panel of in vitro cell-based assays and is an ideal partner to test the potential toxicities of candidate drug compounds. We have developed a number of cell-based toxicity assays and are equipped with the most advanced high content analysis (HCA) platforms, which use automated fluorescence imaging in a high-throughput way and enable us to rapidly and automatically provide high-quality data for safety profiling and dissecting signaling pathways involved in the drug toxicity.
Drug-induced toxicities, with hepatotoxicity and cardiotoxicity being the most common, are the main cause for the withdrawal of drugs from the market. Potential drug candidates often fail because of unacceptable levels of toxicity in the process of drug development. Therefore, prediction of potential toxicities of candidate compounds is of great importance for successful drug development. Early-stage drug toxicity testing can save both time and cost by reducing the chance of failure in preclinical or clinical phase. Compared to in vivo studies, In vitro toxicity tests are believed to be more useful at an early stage due to their short turnaround time and relatively low cost.
Creative Bioarray provides a wide range of in vitro toxicity services, including but not limited to:
High-throughput toxicity screening
With the advantage of simultaneously screening multiple candidate compounds, High-throughput toxicity screening is ideal for the dose-dependent bioactivity evaluation of chemicals in a cost and time efficient way.
High-content toxicity screening
Since drug toxicity is usually a combined phenotype of multiple mechanisms, single experimental approaches are not capable of capturing the complexity involved in cellular toxicity. Creative Bioarray conducts cell-based high-content cytotoxicity screening that can provide multi-parametric information on cellular toxicity using automated fluorescence imaging.
As the primary organ involved in drug detoxification, liver suffers the most from drug toxicity, making drug-induced liver injury (DILI) the leading cause of drug failures. Creative Bioarray has developed a series of assays using primary hepatocytes, HepG2 cell lines and 3D hepatic models to predict DILI.
• 2D-Based Hepatotoxicity Assay
• 3D-Based Hepatotoxicity Assay
Cardiotoxicity is another significant issue during drug development. Based on the iPS/ES cell-derived cardiomyocytes, Creative Bioarray has developed a cardiotoxicity testing platform to predict potential structural damage to the myocardium or arrhythmia.
Neurotoxicity can be hard to notice once the drug enters clinical stage. Thus testing for neurotoxicity is an essential step to avoid later regretful damage. Creative Bioarray focuses on using primary cell models and high/live content imaging to evaluate neurotoxicity.
The kidney plays a key role in eliminating drug metabolites. Several drugs, particularly aminoglycosides, have manifested drug-induced nephrotoxicity. Creative Bioarray has developed a range of nephrotoxicity assays for your candidate compounds in early assessment.
Genotoxicity, compared to other types of toxicity, may result in severe consequences that can be amplified and inherited after exceptionally long periods following exposure. Creative Bioarray offers a series of genotoxicity tests following the OECD test guidelines, including Ames test OECD 471, in vitro chromosomal aberration test OECD 473, and in vitro micronucleus test OECD 487.
The interference of chemicals with the endocrine system may cause developmental malformation, reproduction interference, increased cancer risk, and immune and nervous system malfunction. The sex hormones are most commonly effected by endocrine disruptors. Creative Bioarray can provide services to identify potential endocrine disruptors and evaluate the adverse effects.
Drug-drug interactions (DDI) may cause the loss of drug efficacy or unexpected side effects. Different from usual assays detecting at sub-cellular levels, services at Creative Bioarray are highlighted by assessing DDI at cellular levels. Detection of cytochrome P450 inhibition/induction will be performed with primary or iPS/ES cell-derived hepatocytes.
Other toxicity tests
With the advantage of being a 3D cell culture provider, Creative Bioarray also provides toxicity assays based on 3D cell cultures. If you have any related needs, please feel free to contact us at email@example.com or 1-631-626-9181 to get support from our experienced experts and to find out more about our drug toxicity services. We look forward to working with you in the future.
Cell-Based Drug Discovery:
Drug Toxicity Services: